30 withdrawn. 30 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 30 | Withdrawn 30 |
Follow Mood Disorders: new trials by email Literature Review of Mood Disorders trials Research Report on Mood Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dopamine D3 Receptor Occupancy in Bipolar Depression Cariprazine - Bipolar Depression | Phase 4 | Withdrawn | New York State Psychiatric Institute | 2026-01-06 | 2026-04-14 | |
| Mood Disorders in Head and Neck Cancer Patients Venlafaxine - Depressive Disorder, Head and Neck Cancer | Phase 4 | Withdrawn | University of Alabama at Birmingham | 2024-01-05 | 2025-02-04 | |
| VA Aripiprazole vs Esketamine for Treatment Resistant Depression Esketamine, Aripiprazole - Depressive Disorder, Major | Phase 4 | Withdrawn | VA Office of Research and Development | 2023-10-27 | 2024-01-05 | |
| Pilot Study 1: Efficacy and Safety of Sublingual Dexmedetomidine (BXCL501) for the Treatment of Agitation in the Emergency Department Sublingual film containing dexmedetomidine (BXCL501) - Agitation, Schizophrenia | Phase 4 | Withdrawn | Brigham and Women's Hospital | 2023-09-01 | 2026-01-28 | |
| Preoperative Ketamine and Perioperative Depression Ketamine Group, Midazolam injection - Depressive Disorder | Phase 4 | Withdrawn | Northwestern University | 2022-09-01 | 2023-02-06 | |
| Open-label Brexpiprazole fMRI Trial in Adults With Major Depressive Disorder and Anxiety Brexpiprazole - Major Depressive Disorder (MDD) | Phase 4 | Withdrawn | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2022-08-29 | 2023-01-30 | |
| Cannabidiol for Treatment Resistant Depression Active study drug ( oral CBD), matching placebo - Treatment Resistant Depression | Phase 4 | Withdrawn | University of Alabama at Birmingham | 2021-07-01 | 2021-07-19 | |
| A PET Study With [11C]PBR-28 and an Experimental Medication, Ethyl Eicosapentaenoic Acid Ethyl Eicosapentaenoic Acid - Bipolar Disorder | Phase 4 | Withdrawn | New York State Psychiatric Institute | 2021-03-19 | 2022-10-14 | |
| Leveraging EEG for Antidepressant Prediction With Sertraline and Escitalopram Sertraline, Escitalopram - Major Depressive Disorder | Phase 4 | Withdrawn | Alto Neuroscience | 2020-10-15 | 2020-10-19 | |
| Leveraging EEG for Antidepressant Prediction With Duloxetine and Bupropion Duloxetine, Bupropion - Major Depressive Disorder | Phase 4 | Withdrawn | Alto Neuroscience | 2020-10-15 | 2020-10-19 | |
| A Study to Evaluate Multimodal Neuroimaging Parameters in Women With Postpartum Depression Who Are Receiving ZULRESSO™ (Brexanolone) Brexanolone - Postpartum Depression | Phase 4 | Withdrawn | Sage Therapeutics | 2020-02-01 | 2020-08-18 | |
| EnBrace HR for PMS With Prominent Mood Symptoms or Menstrual Related Mood Disorders EnBrace HR Softgel - Premenstrual Syndrome, Premenstrual Dysphoric Disorder | Phase 4 | Withdrawn | Massachusetts General Hospital | 2019-11-01 | 2020-01-02 | |
| Vortioxetine Monotherapy for Major Depressive Disorder in Type 2 Diabetes Vortioxetine - Type2 Diabetes, Major Depressive Disorder | Phase 4 | Withdrawn | Todd Doyle | 2019-07-01 | 2022-11-29 | |
| Suvorexant (Belsomra) for the Treatment of Bipolar Depression With Insomnia Suvorexant (Belsomra), Placebo - Bipolar Disorder, Insomnia | Phase 4 | Withdrawn | Massachusetts General Hospital | 2019-02-26 | 2021-02-21 | |
| A Pilot Study Investigating the Efficacy of Minocycline and N-Acetyl Cysteine for Bipolar Depression N-acetylcysteine, Minocycline, Placebo - Bipolar Disorder, Bipolar Depression | Phase 4 | Withdrawn | Massachusetts General Hospital | 2017-08-09 | 2026-07-24 | |
| Creatine for Treatment of Depression Associated With Type 2 Diabetes Creatine Monohydrate - Major Depressive Disorder | Phase 4 | Withdrawn | University of Utah | 2017-08-01 | 2024-06-11 | |
| Open-Label Study of Latuda for the Treatment of Mania in Children and Adolescents 6-17 Years Old Latuda (Lurasidone) - Mania, Bipolar I | Phase 4 | Withdrawn | Massachusetts General Hospital | 2017-01-01 | 2018-07-20 | |
| Neural Correlates for Therapeutic Mechanisms of Lithium in Bipolar Disorder Lithium - Bipolar Disorder | Phase 4 | Withdrawn | Ewha Womans University | 2015-06-01 | 2018-02-09 | |
| Efficacy and Safety of Paroxetine Controlled Release for Major Depressive Disorder in Irritable Bowel Syndrome Patients Paroxetine CR - Depressive Disorder | Phase 4 | Withdrawn | GlaxoSmithKline | 2014-01-01 | 2014-07-16 | |
| A Comparison of Medication Augmentation and PST in the Treatment of Depression in Older Adults Aripiprazole, Bupropion, Problem Solving Therapy - Major Depressive Disorder, Dysthymic Disorder | Phase 4 | Withdrawn | New York State Psychiatric Institute | 2013-08-01 | 2019-04-18 |
Showing 20 of 30. Sign in to see all of them.
Bipolar Disorder (12) · Depressive Disorder, Major (11) · Depressive Disorder (4) · Depression (3) · Depressive Disorder, Treatment-Resistant (3) · Diabetes Mellitus, Type 2 (2) · Alcoholism (1) · Anxiety Disorders (1) · Depression, Postpartum (1) · Diabetes Mellitus (1) · Dysthymic Disorder (1) · Head and Neck Neoplasms (1) · Mania (1) · Premenstrual Dysphoric Disorder (1) · Premenstrual Syndrome (1)
Mental Disorders (30) · Depressive Disorder (15) · Bipolar and Related Disorders (12) · Behavior (4) · Behavioral Symptoms (4) · Nervous System Diseases (3) · Pathological Conditions, Signs and Symptoms (3) · Endocrine System Diseases (2) · Glucose Metabolism Disorders (2) · Metabolic Diseases (2) · Neurobehavioral Manifestations (2) · Neurologic Manifestations (2) · Nutritional and Metabolic Diseases (2) · Signs and Symptoms (2)
Ketamine (3) · Lithium (3) · Valproic Acid (3) · Aripiprazole (2) · Bupropion (2) · Creatine (2) · Venlafaxine Hydrochloride (2) · Acetylcysteine (1) · Citalopram (1) · Dexetimide (1) · Docosahexaenoic Acids (1) · Duloxetine Hydrochloride (1) · Escitalopram (1) · Esketamine (1) · Lithium Carbonate (1)
Massachusetts General Hospital (5) · New York State Psychiatric Institute (3) · Alto Neuroscience (2) · University of Alabama at Birmingham (2) · University of Utah (2) · Bo-Hyun Yoon (1) · Brigham and Women's Hospital (1) · Essentia Health (1) · Ewha Womans University (1) · GlaxoSmithKline (1) · Lawson, William B., M.D., PhD, DFAPA (1) · Mayo Clinic (1) · Northwestern University (1) · Nova Scotia Health Authority (1) · Otsuka Pharmaceutical Development & Commercialization, Inc. (1)
United States (15) · South Korea (2) · Canada (1)
Corey Keller, MD, PhD (2) · Perry F Renshaw, MD, PhD, MBA (2) · Andrew A Nierenberg, M.D. (1) · Bo-Hyun Yoon, Doctor (1) · Bret Rutherford, MD (1) · Charles Hogue, MD (1) · Claire O'Donovan, MD, FRCPC (1) · Gustavo Kinrys, MD (1) · Ihsan Salloum, MD MPH (1) · Janet Wozniak, M.D. (1) · Jessica Grayson, MD (1) · Mark A Frye, MD (1) · Marlene P Freeman, MD (1) · Martin Lan, MD (1)
R44MH123373 (1)